

After page 37 and before the claims, please insert the two page sequence listing submitted in the Response filed on June 5, 1996, and please renumber the pages as needed.

IN THE CLAIMS:

Please cancel claims 1 to 11 without prejudice or disclaimer.

Please add the following new claims:

- B1* C
12. A method for the inhibition of viral proliferation which comprises treating a patient with a composition containing an antiviral effective amount of a human-type serine protease inhibitor comprising a secretory leukocyte protease inhibitor (SLPI).
C 13. A method for the inhibition of retroviral proliferation which comprises treating a patient with a composition containing an antiretroviral effective amount of a human-type serine protease inhibitor comprising a secretory leukocyte protease inhibitor (SLPI).--

REMARKS

After the amendments above are entered, claims 12 and 13 will be pending. Support for new claims 12 and 13 is found throughout the specification.

The Examiner required compliance with the sequence listing rules by requesting that the sequence listing be added to the specification. Office Action at page 2, second paragraph. In the amendments above, applicants request entry of the sequence listing into the specification.

The Examiner points out various formal requirements or objections at the last paragraph of page 2 of the Office Action. First, the Examiner contends that the term "PEGylated" at lines 15 and 17 of page 7 is undefined. The terms "PEGylated" and